Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study (Q42646462)

4 November 2017

Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study (English)

1 reference

transthyretin amyloidosis

4 November 2017

1 reference

1 reference

6

1 reference

4 November 2017

8

1 reference

4 November 2017

9

1 reference

4 November 2017

Laura Obici

1

1 reference

4 November 2017

Andrea Cortese

2

1 reference

4 November 2017

Alessandro Lozza

3

1 reference

4 November 2017

J Lucchetti

4

1 reference

4 November 2017

Marco Gobbi

5

1 reference

4 November 2017

Stefano Perlini

7

1 reference

4 November 2017

2 May 2012

1 reference

4 November 2017

1 reference

4 November 2017

19 Suppl 1

1 reference

4 November 2017

34-36

1 reference

Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses

4 November 2017

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2012.678508

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2012.678508

4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2012.678508

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13506129.2012.678508

10.3109/13506129.2012.678508

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference